Metoprolol Succinate vs. Carvedilol: The Fourth Pillar for a Choir Director with COPD
New HFrEF and stable moderate COPD, already on three of the four GDMT pillars. The beta-blocker decision turns out to rest less on a settled mortality comparison than most of the group assumed going in.
M.A., a 74-year-old woman, has directed the choir at her church for more than twenty years — three services most Sundays, weekly rehearsals, and enough breath control built up over decades that she still teases the younger sopranos about theirs. Six weeks ago she came in short of breath doing exactly the stair-climbing she'd always managed without thinking about it, and a workup found a new diagnosis: nonischemic HFrEF with an EF of 32%. She has moderate COPD, diagnosed twelve years ago after thirty pack-years of smoking she quit a decade back — stable on inhaled tiotropium and a long-acting beta-agonist, no exacerbation requiring steroids or hospitalization in over two years, FEV1 60% predicted at her most recent pulmonary function test. She is already on sacubitril/valsartan, dapagliflozin, and spironolactone, started and titrated over the past six weeks; the fourth pillar of GDMT — a beta-blocker — is the piece still missing, and the choice of which one has turned into a real disagreement.
Metoprolol succinate and carvedilol both improve survival in HFrEF, but they reach that outcome through different receptor profiles. Metoprolol succinate is beta-1 selective; carvedilol blocks beta-1, beta-2, and alpha-1 together, and that beta-2 component is exactly the receptor her rescue inhaler and her long-acting beta-agonist work through; her tiotropium, being an antimuscarinic, does not. A randomized crossover trial in patients with chronic heart failure and coexisting COPD found measurable differences on switching between these agents — airway function moved on exposure to carvedilol in a way it didn't with the beta-1-selective drugs. Carvedilol's reputation for superior mortality benefit traces largely to the COMET trial, but COMET compared carvedilol against metoprolol tartrate, the short-acting formulation, not the long-acting succinate salt actually used in modern HFrEF therapy — a comparison that doesn't cleanly settle which drug is better against the formulation M.A. would actually be prescribed.
Heart failure clinic, beta-blocker selection
I'd default to carvedilol. It carries this field's historical reputation for the strongest mortality benefit of the beta-blockers we use in HFrEF, and its alpha-1 blockade gives it broader neurohormonal coverage than a beta-1-selective agent alone. COPD without active bronchospasm hasn't reliably excluded patients from that benefit in the large trials that established it.
I'm not dismissing the airway concern — I'm saying stable COPD, on its own, hasn't historically been enough to override carvedilol's outcomes reputation in practice.
"Not excluded from a trial" isn't the same as "no measurable effect." The crossover data are direct — switching patients with CHF and COPD onto carvedilol produced real changes in airway function that beta-1-selective agents didn't. Her COPD is stable, not absent, and stable is exactly the state you can destabilize with an avoidable exposure. If an equally evidence-backed cardioselective option exists, I don't see the case for accepting that risk.
I'm not arguing carvedilol is dangerous in every COPD patient — I'm arguing the burden of proof should sit with the choice that has a demonstrated airway effect, not the one that doesn't.
I think the mortality-advantage premise both of you are debating around doesn't actually hold up. COMET is the trial usually cited for carvedilol's edge, and COMET compared it against metoprolol tartrate — the short-acting salt nobody actually starts a new HFrEF patient on anymore, not the succinate formulation in front of us today. Once you name that gap, there's no strong evidence forcing a choice on mortality grounds between carvedilol and succinate specifically. That doesn't make carvedilol wrong — it means the tie should go to the option with less unnecessary airway risk for this particular patient.
Agreed: start metoprolol succinate 12.5mg daily with a slow up-titration schedule, continue her existing GDMT and COPD maintenance therapy unchanged, and monitor for both heart-failure symptom response and any change in her respiratory status at each titration step.
Not agreed, and carried forward explicitly rather than smoothed over:
Still prefers carvedilol as a general first choice in HFrEF patients without COPD, and does not treat today's reasoning as a reason to change that default going forward.
All three voices agreed carvedilol becomes the next step, at which point the airway-risk question would need to be revisited directly rather than avoided.
The Clinical Pharmacologist's reframing of the COMET comparator was accepted by the other two as accurate, but the Heart Failure Cardiologist noted explicitly that a weaker evidence case for carvedilol's superiority isn't the same as an evidence case against it — the decision today was resolved by her actual COPD, not by carvedilol being disqualified in general.